Women Infertility – Pipeline by Competitor Information, Analysis, and Insights to Formulate Effective R&D Strategies 2017

WiseGuyReports.com adds Exclusive Research on “Women Infertility” reports to its database.

PUNE, INDIA - October 13, 2017 /MarketersMedia/ —

SUMMARY

WiseGuyReports published new report, titled “Women Infertility - Pipeline Review, H2”

Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Pipeline Review, H2 2017, provides an overview of the Women Infertility (Women's Health) pipeline landscape.
Infertility refers to failure to conceive over the course of one full year. Women infertility is caused due to damage of fallopian tubes, ovulation disorders (polycystic ovary syndrome) and endometriosis. Symptoms include abnormal periods, weight gain, back pain, pelvic pain, and cramping. Risk factor of infertility includes smoking tobacco, using alcohol, being overweight, being exposed to toxins, certain medical conditions, including tumors and chronic illnesses. Treatment includes medications to stimulate ovulation and hormone therapies.

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385306-women-infertility-pipeline-review-h2-2017

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Women Infertility - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 7, 16, 14, 1, 22, 9 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 5 and 3 molecules, respectively.
Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)

Key points to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents
Introduction
Women Infertility - Overview
Women Infertility - Therapeutics Development
Women Infertility - Therapeutics Assessment
Women Infertility - Companies Involved in Therapeutics Development
Women Infertility - Drug Profiles
Women Infertility - Dormant Projects
Women Infertility - Discontinued Products

..CONTINUED

About Us

Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: wiseguyreports
Address: Office No. 528, Amanora Chambers Pune - 411028 Maharashtra, India
Phone: +44 208 133 9349

Source URL: https://marketersmedia.com/women-infertility-pipeline-by-competitor-information-analysis-and-insights-to-formulate-effective-rd-strategies-2017/249960

For more information, please visit https://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 249960

Latest News

Global stocks mixed as trade disputes worry investors

Jun 22, 2018

SEOUL, South Korea — Global stocks were mixed Friday as investors remained wary over trade disputes between China and the U.S. as well as between the U.S. and Europe that could hurt corporate profits and jobs. Some markets rebounded slightly but were unable to recoup their heavy losses for the week. KEEPING SCORE: Britain's FTSE 100 rose 0.7 percent in early trading to 7,607.88 and France's CAC 40 advanced 0.7 percent to 5,355.21. Germany's DAX gained 0.4 percent to 12,563.75. Futures augured gains on Wall Street. S&P futures rose 0.5 percent while Dow futures also advanced 0.5 percent. ASIA'S DAY:...

Turkey heads to landmark presidential, parliamentary vote

Jun 22, 2018

ISTANBUL — President Recep Tayyip Erdogan, who has never lost an election, is taking a gamble that will consolidate his hold on power in Turkey if he emerges victorious from Sunday's landmark presidential and parliamentary vote. But winning the election he called more than a year early might not be as straightforward as he might have hoped. For the first time, Turkey's disparate opposition — made up of secularists, nationalists, Islamists and Kurds — is showing a more united front, with some parties joining forces. Meanwhile the economy, to which Erdogan could once point as a shining example of his...

Asian stocks down as multiple trade disputes worry investors

Jun 22, 2018

SEOUL, South Korea — Asian stocks fell Friday following Wall Street losses overnight as investors were still wary over trade disputes between China and the U.S. as well as between the U.S. and Europe that could hurt corporate profit and jobs. KEEPING SCORE: Japan's Nikkei 225 lost 0.9 percent to 22,500.45 while Hong Kong's Hang Seng index edged down 0.2 percent to 29,257.41. Shanghai Composite Index added 0.2 percent to 2,881.13 but it was still more than 5 percent lower than the start of the week. South Korea's Kospi rose 0.3 percent to 2,344.55 after losing more than 3 percent...

Fed finds biggest US banks strong enough to survive shock

Jun 22, 2018

WASHINGTON — The Federal Reserve says that all of the 35 largest U.S. banks are fortified enough to survive an economic shock and keep on lending. Banks' hypothetical losses from credit cards increased in the latest "stress tests," however. The first round of the central bank's annual stress tests, released Thursday, shows that as a group, the 35 big banks have benefited from a steadily recovering economy to gain strength and build up capital buffers against unexpected losses. It was the eighth annual check-up for the banks, mandated by Congress after the 2008 financial crisis that triggered the Great Recession....

The Latest: Interior links reorganization plan to Obama

Jun 22, 2018

WASHINGTON — The Latest on the Trump administration's proposal to reorganize the federal government (All times local): 4:10 p.m. The Trump administration is citing an endorsement from unlikely source — former President Barack Obama — as it touts a plan to reorganize the federal government. One element of the plan announced Thursday would transfer the National Marine Fisheries Service to the Interior Department and essentially merge it with the Fish and Wildlife Service, another Interior agency. Obama made a similar proposal in his first term. In his 2011 State of the Union address, Obama said Interior handles salmon in fresh...

Broaden News
Search

Manage The Numbers is the world’s fastest-growing finance news website, featuring the latest money and market news, along with in-depth analysis so you can make the best decision.

Contact us: sales@managethenumbers.com

Subscribe to our newsletter!

Name

Email